Add this event to your calendarDec 7, 2017 10 AM (PT)Enabling efficient Discovery and Clinical Research in drug response: Application of a targeted Next-Generation Sequencing Assay for Pharmacogenetics
超级大乐透中奖规则 www.slf2t.cn Pharmacogenetic (PGx) testing enables researchers to understand a
person’s genetic propensity for a therapeutic response or an adverse
reaction to particular medications. Recently the NIH’s Precision
Medicine Initiative has begun a nationwide effort to individualize a
subject’s treatment program, while the FDA has already included PGx
information in over one hundred drug labels. Serious drug reaction
events are likely to become more prevalent as more drugs become
available and the number of pharmaceuticals each person is taking
increases. To understand the occurrence of these events, sequencing
genomic regions associated with metabolism of a wide-spectrum of drug
classes can help inform clinical researchers, and better characterize
the frequency of known and novel haplotypes within validated genes
involved in drug metabolism pathways.
presentation, we will describe a method and workflow for targeted
pharmacogenetic gene sequencing using Kailos’ TargetRichTM?PGxComplete assay.
Add this event to your calendarNov 14, 2017 9 AMNext-generation solutions for the next era of sequencing
The latest NovaSeq advancements have arrived—delivering unprecedented
scalability and flexibility for next-generation sequencing (NGS).
Discover how the S4 flow cell allows you to use the NovaSeq 6000
System to take your research to the next level.
Join Gary Schroth, Illumina Distinguished Scientist, to learn about
these latest advancements with the NovaSeq 6000 System. See how the S4
can provide you the highest throughput of any sequencer. Finally, with
the new NovaSeq Xp workflow, you can expand your research, giving you
more flexibility than ever before.
Add this event to your calendarJun 27, 2017 9:00 AM (PT)The Effective Implementation of NIPT into a Busy Practice: An Obstetrician Perspective
Medical societies now recommend that all women, regardless of age, be
offered screening and diagnostic testing for aneuploidy during
pregnancy.1-2?Noninvasive prenatal testing (NIPT) is a newer screening
option that utilizes the presence of cell-free DNA in a pregnant
woman’s blood originating from the pregnancy. Whole-genome
sequencing-based NIPT can screen for common aneuploidies (trisomy 21,
trisomy 18, trisomy 13, and certain sex chromosome aneuploidies) with
greater accuracy than other available screening modalities, resulting
in a significant reduction in false positive rates and, subsequently,
potential reduction in invasive procedures in healthy pregnancies.3
In this webinar, Tina Ziainia, MD, FACOG, an
Obstetrician-Gynecologist affiliated with Sharp HealthCare, provides
insight and expertise on successfully implementing NIPT into a busy
practice. Having been in practice for over 17 years and having offered
NIPT since 2013, she’ll also discuss prenatal screening options,
review the latest ACOG and ACMG screening guidelines, and identify
helpful resources for both you and your patients.
1. Practice Bulletin No. 163: Screening for Fetal
Aneuploidy.?Obstet Gynecol. 2016;127(5):979-981.
2. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal
screening for fetal aneuploidy, 2016 update: a position statement of
the American College of Medical Genetics and Genomics.?Genet
Med. 2016: doi:10.1038/gim.2016.97. 3. Bianchi DW, Rava RP,
Sehnert AJ. DNA sequencing versus standard prenatal aneuploidy
screening.?N Engl J Med. 2014;371(6):578.
Add this event to your calendarMay 30, 2017 16:00 CETImplementing TruSight Tumor 15 (TST15) for solid tumor profiling
To gain efficiency in the lab, multigene testing is rapidly being
adopted for tumor profiling. TruSight Tumor 15 (TST15) is a
next-generation sequencing (NGS)-based assay which includes the 15
most common cancer biomarkers, and delivers a streamlined solution for
Join the webinar to find out about:
Results of the multicenter validation study on TruSight Tumor
15 across European pathology labs
Dr. von Leitner's
perspective on the choice to adopt TruSight Tumor 15 and the steps
involved for implementation at her laboratory in Hamburg
Upcoming software update supporting amplification analysis for
the three critical genes (ERBB2, EGFR & MET), as well as support
for automated library prep.?
Add this event to your calendarMay 23, 2017 16.00 CEST (Central European Summer Time)Dissecting the genetic basis of Brugada Syndrome
Brugada Syndrome belongs to a family of rare inherited cardiac
disorders that can lead to sudden cardiac death. Rare genetic variants
in the SCN5A gene can be identified in ~20%* of cases with Brugada
Syndrome, while the genetic basis in the others remains unresolved.
Ongoing studies, combining data from multiple genomic methods, are
helping to elucidate the genetic basis of Brugada Syndrome and other
complex cardiac disorders with the aim of improving patient care in
Register for the webinar to hear Professor Connie Bezzina present
data from her laboratory and ongoing collaborative studies with the
Brugada Syndrome Genetics Consortium.
Add this event to your calendarMay 2, 2017 9 AM (PT)iDTECT Blood, a sample-to-report next-generation sequencing (NGS) solution for precision diagnostics in infectious diseases
This webinar will provide an overview of the development, validation
and clinical evaluation of PathoQuest’s iDTECT?Blood. This CE IVD test
represents an application of NGS-based shotgun metagenomics to the
field of infectious disease diagnosis. The test provides
microbiologists and clinicians a precision diagnostics tool allowing
individualized antimicrobial treatment decisions in patients where
current microbiological methods frequently fail to identify a
responsible pathogen. Both the sample preparation and the
bioinformatic pipeline have been optimized to provide high sensitivity
and accuracy and an actionable report. Clinical results from a
prospective study recently published in Clinical Microbiology and
Infection will also be discussed.